Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Bayer, Nuvisan to create drug discovery research unit in Berlin

By Sean Whooley | February 12, 2020

Bayer (ETR:BAYN) announced that it entered into a definitive agreement to transfer some of its small molecule research unit to Nuvisan for an undisclosed amount.

The agreement is slated to lay a foundation for Nuvisan to establish the Berlin-based research unit and support Bayer’s focus on the flexibility and productivity of its research & development operating model, according to a news release.

Nuvisan is a company that provides services for clinical studies, laboratory services and contract manufacturing at multiple sites in Germany and France. Its new Berlin unit consists of about 400 workplaces with a fully operational team specializing in small molecule research. The research center includes capabilities and capacities across the drug discovery value chain.

Bayer plans to retain significant research activities in Berlin, the city which headquarters its pharmaceuticals division, along with one of its major global research sites. It also intends to cooperate with Nuvisan to build the new research center in Berlin, with the transaction expected to close sometime in mid-2020.

“With Nuvisan we have found an excellent partner with a clear plan to build up a strong full-fledged research unit in Berlin together with our dedicated team of scientists,” Bayer pharmaceuticals division executive committee member & head of R&D Dr. Joerg Moeller said in the news release. “Nuvisan shares our vision that the new research center can become an important player in research partnering based on the joint know-how and the capabilities of our highly qualified scientists.”

Nuvisan CEO & managing partner Dietrich Bruchmann said the company will not only welcome a high-performance research team, but also obtain access to excellent specialty know-how and technology.

“The acquisition of the research unit and its location at the Bayer R&D campus will create an operational hub in the scientific excellence cluster Berlin and allow us to significantly accelerate the drug development process from discovery to clinical trials,” Bruchmann said.


Filed Under: Drug Discovery, Drug Discovery and Development
Tagged With: Bayer, Nuvisan
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

CNS
The CNS drug development drum beat is getting louder
DeepMind
7 ways DeepMind’s AlphaFold is being used in life sciences
Biomarker
Bioanalytical method development and validation using Quanterix’s Simoa platform 
FDA logo
FDA could approve MDMA and psilocybin in 2 years

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50